<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs</journal-id><journal-id journal-id-type="iso-abbrev">Drugs</journal-id><journal-title-group><journal-title>Drugs</journal-title></journal-title-group><issn pub-type="ppub">0012-6667</issn><issn pub-type="epub">1179-1950</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29532439</article-id><article-id pub-id-type="pmc">5915521</article-id><article-id pub-id-type="publisher-id">894</article-id><article-id pub-id-type="doi">10.1007/s40265-018-0894-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Adis Drug Evaluation</subject></subj-group></article-categories><title-group><article-title>OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Frampton</surname><given-names>James E.</given-names></name><address><email>demail@springer.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Silberstein</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0372 1209</institution-id><institution-id institution-id-type="GRID">grid.420067.7</institution-id><institution>Springer, </institution></institution-wrap>Private Bag 65901, Mairangi Bay, Auckland, 0754 New Zealand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2166 5843</institution-id><institution-id institution-id-type="GRID">grid.265008.9</institution-id><institution>Jefferson Headache Center, </institution></institution-wrap>Philadelphia, PA USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>78</volume><issue>5</issue><fpage>589</fpage><lpage>600</lpage><permissions><copyright-statement>&#x000a9; Springer Nature 2018, corrected publication April/2018</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">An intramuscular formulation of onabotulinumtoxinA (onabotA; Botox<sup>&#x000ae;</sup>) is currently the only therapy specifically approved for the prevention of headaches in adults with chronic migraine (CM) in the EU and North America. This article provides a narrative review of relevant data on the drug in this indication from an EU perspective. OnabotA was originally approved on the basis of pooled data from two phase III studies (PREEMPT 1 and 2). In these pivotal studies, injection of up to five cycles of onabotA (155&#x02013;195 U/cycle) at 12-week intervals was generally well tolerated and effective in producing statistically significant and clinically meaningful improvements in headache symptoms, acute headache pain medication usage, headache impact and health-related quality of life in adults with CM, of whom approximately two-thirds were acute medication overusers and approximately one-third had failed to respond to&#x02009;&#x02265;&#x02009;3 prior oral prophylactic therapies. More recently, the efficacy and tolerability of onabotA over a period of 1&#x000a0;year in the PREEMPT programme has been substantiated and extended by the results of a long-term phase IV study (COMPEL), in which patients received up to nine treatment cycles over a period of 2&#x000a0;years, and by findings from several real-world clinical practice studies from Europe, including the prospective multinational REPOSE and CM-PASS studies. In conclusion, the totality of evidence from clinical trials and real-world studies indicates that onabotA is an effective and generally well tolerated option for the prevention of CM that may be particularly useful for patients who have previously failed to respond to or are intolerant of commonly prescribed oral prophylactics.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing AG, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Intramuscular onabotulinumtoxinA: clinical considerations in CM prevention</title><p id="Par2">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Only therapy specifically approved for the prevention of headaches in adults with CM in the EU</td></tr><tr><td align="left">Therapy involves regular (3-monthly) injections</td></tr><tr><td align="left">Efficacy and tolerability in large clinical trials confirmed in large real-world studies</td></tr><tr><td align="left">Beneficial in patients regardless of whether or not they are acute medication overusers</td></tr><tr><td align="left">Neck pain, (facial-) muscle weakness and eyelid ptosis are the most common treatment-related adverse events</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Migraine, a disabling neurological disorder characterized by severe headache and associated symptoms (e.g. nausea, vomiting, photophobia and/or phonophobia) [<xref ref-type="bibr" rid="CR1">1</xref>], exists along a continuum between episodic and chronic (i.e. more frequent, severe and burdensome) forms of the disease [<xref ref-type="bibr" rid="CR2">2</xref>]. According to the current International Headache Society classification of headache disorders (ICHD-3), chronic migraine (CM) is defined as headache on&#x02009;&#x02265;&#x02009;15&#x000a0;days per month for&#x02009;&#x0003e;&#x02009;3&#x000a0;months, of which&#x02009;&#x02265;&#x02009;8&#x000a0;days meet the criteria for migraine with or without aura and/or respond to migraine-specific treatment, occurring in a patient with a history of at least five prior migraine attacks not attributed to another causative disorder or medication overuse [<xref ref-type="bibr" rid="CR1">1</xref>]. It affects&#x02009;&#x02248;&#x02009;1&#x02013;2% of the general population [<xref ref-type="bibr" rid="CR3">3</xref>] and usually evolves from episodic migraine (EM; defined as&#x02009;&#x0003c;&#x02009;15 headache days per month) [<xref ref-type="bibr" rid="CR4">4</xref>], with chronification occurring in&#x02009;&#x02248;&#x02009;3% of patients with EM annually [<xref ref-type="bibr" rid="CR5">5</xref>]. CM is classified as a distinct clinical entity [<xref ref-type="bibr" rid="CR6">6</xref>]; patients with CM experience more headache days, but also increased headache-related disability, reduced health-related quality of life (HR-QOL) and greater co-morbidity than those with EM [<xref ref-type="bibr" rid="CR7">7</xref>]. CM is associated with higher healthcare resource utilization and socioeconomic burden compared with EM [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Historically, only a minority of patients with CM have been correctly diagnosed [<xref ref-type="bibr" rid="CR8">8</xref>]; however, a simple case-finding tool that accurately identifies most patients with CM has recently been developed and validated [Identify Chronic Migraine (ID-CM)] [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par4">The management of CM centres around three main approaches: lifestyle modification and behavioural therapy; use of acute medications to relieve or ameliorate the symptoms of a migraine attack that has already begun; and the use of preventative pharmacotherapies to reduce the frequency, duration and severity of attacks, thereby limiting the need for acute medications, as these may be causing concurrent medication overuse headache (MOH) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Various oral agents, including &#x003b2;-adrenoreceptor antagonists and anticonvulsants, have been shown to be effective in the prevention of migraine in general [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] and are recommended for use as first- or second-line therapies by EU guidelines [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. However, none of these agents are specifically licenced for the prevention of CM in this region. Moreover, they have shortcomings in terms of efficacy, tolerability and adherence; additional pharmacological and non-pharmacological interventions have been investigated in response to the long-identified need for more effective therapies for patients with CM [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par5">OnabotulinumtoxinA (hereafter referred to as onabotA) [Botox<sup>&#x000ae;</sup>], a formulation of botulinum toxin type A (BoNT/A) administered by intramuscular injection, is currently the only therapy specifically approved for the prevention of CM (i.e. headaches in adults with CM) in the EU [<xref ref-type="bibr" rid="CR18">18</xref>] and North America [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. This article briefly summarizes the pharmacological properties of onabotA and, from an EU perspective, provides a narrative review of data from clinical trials and real-world studies pertaining to its efficacy and tolerability in the prevention of CM. The developmental history of onabotA for CM has been described elsewhere [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec2"><title>Pharmacological Properties of OnabotulinumtoxinA</title><p id="Par6">The pharmacodynamic properties of onabotA include a well characterized temporary muscle relaxant effect, which results from the toxin entering motor nerve terminals and cleaving nine amino acids from the C-terminus of the Soluble NSF-Attachment Protein Receptor (SNARE) protein SNAP25 (SNAP25<sub>206</sub>) to yield SNAP25<sub>197</sub>, thereby disrupting exocytosis and blocking neurotransmitter release [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par7">The exact mechanism of action whereby extracranial administration of onabotA prevents headaches in patients with CM is being elucidated [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par8">The most widely promulgated notion is founded on the phenomena of central and peripheral sensitization within the trigeminovascular system, both of which have been implicated in the pathophysiology of migraine/CM [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. According to this theory, injection of onabotA in the trigeminally-innervated cranio-facial-cervical region blocks peripheral sensitization as a result of inhibiting the release of pain-mediating peptides, especially calcitonin gene-related protein (CGRP), from peripheral nociceptive neurones; this reversal of peripheral sensitization leads indirectly to reversal of central sensitization [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. In addition to inhibiting the release of pain-mediating peptides, onabotA may reduce peripheral sensitization by interfering with the integration of relevant sensory receptors and ion channels [e.g. transient receptor potential cation channel vanilloid subfamily member 1 (TRPV1) and transient receptor potential cation channel ankyrin subfamily member 1 (TRPA1)] on nociceptive nerve endings [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Both actions are thought to involve inhibition of SNARE-mediated synaptic vesicle trafficking by onabotA [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par9">An alternative hypothesis, namely that onabotA exerts a direct effect on central pain processing as a result of retrograde transport in peripheral nociceptive neurones and transcytosis to second-order neurones [<xref ref-type="bibr" rid="CR31">31</xref>], has received support from an in vitro study that examined the trafficking of clostridial neurotoxins (including onabotA) in central neurones grown in microfluidic devices [<xref ref-type="bibr" rid="CR32">32</xref>]. However, an in vivo study that used a highly selective antibody for SNAP25<sub>197</sub> combined with 3-dimensional imaging and quantitative analysis found no evidence in favour of transcytosis [<xref ref-type="bibr" rid="CR33">33</xref>]. Under the prevailing experimental conditions, onabotA was confined to primary motorneurones following peripheral administration in rats; any suggestion of distal activity was due to limited systemic spread of the toxin at higher doses [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par10">Interestingly, distinct structural and functional brain changes have been observed in patients with CM who respond to prophylactic therapy with onabotA (i.e. revert to EM) compared with those who do not respond to therapy [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par11">The pharmacokinetics of onabotA have not been studied due to the neurotoxic nature of the product. However, little systemic absorption of onabotA is believed to occur following intramuscular injection of therapeutic doses; it is probably metabolised by proteases and the molecular components recycled through normal metabolic pathways [<xref ref-type="bibr" rid="CR35">35</xref>]. Like other BoNT/A products, onabotA exhibits a low immunogenic potential [<xref ref-type="bibr" rid="CR36">36</xref>], as exemplified by the fact that none of 496 analysable patients with EM or CM had a confirmed positive test for neutralizing antibodies after up to three 12-week treatment cycles in phase II studies [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec3"><title>Therapeutic Efficacy of OnabotulinumtoxinA</title><p id="Par12">In terms of key clinical trials, the efficacy of injected onabotA for headache prevention in adults with CM has been evaluated over a period of 1&#x000a0;year in the pivotal phase III PREEMPT 1 and 2 studies (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>) and, longer-term, over a period of 2&#x000a0;years in the phase IV COMPEL study (Sect. <xref rid="Sec6" ref-type="sec">3.2</xref>). In addition, a number of real-world studies have examined the effectiveness of onabotA for the prevention of CM in routine clinical practice in Europe, typically for periods of up to 2&#x000a0;years (Sect. <xref rid="Sec7" ref-type="sec">3.3</xref>).</p><sec id="Sec4"><title>PREEMPT Trials</title><p id="Par13">The multicentre PREEMPT 1 [<xref ref-type="bibr" rid="CR38">38</xref>] and 2 [<xref ref-type="bibr" rid="CR39">39</xref>] trials together comprised the PREEMPT clinical trial programme. Apart from the designation of the primary and secondary endpoints (discussed in detail elsewhere [<xref ref-type="bibr" rid="CR17">17</xref>]), these studies were identical in design; their findings have been analysed separately [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>] or pooled [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par14">Briefly, both studies consisted of a 24-week randomized, double-blind, placebo-controlled phase followed by a 32-week open-label extension phase [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Eligible patients were men and women aged 18&#x02013;65&#x000a0;years with CM defined according to the then-prevailing (2004) ICHD-2 criteria [<xref ref-type="bibr" rid="CR45">45</xref>]. To enter the placebo-controlled phase, they were required to have had (1)&#x02009;&#x02265;&#x02009;15 headache days (with each day consisting of&#x02009;&#x02265;&#x02009;4&#x000a0;h of continuous headache and with&#x02009;&#x02265;&#x02009;50% of days being migraine or probable migraine days) and (2) at least four distinct headache episodes (with each episode lasting&#x02009;&#x02265;&#x02009;4&#x000a0;h) during a 28-day (i.e. 1&#x000a0;month) baseline period prior to randomization; patients were stratified according to whether or not they met the protocol definition for overuse of acute headache pain medications during this period [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par15">OnabotA was injected into 31 sites across seven specific head/neck muscle areas (frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal) using a fixed-dose/fixed-site approach (5 U per injection; one injection per site). Up to eight additional injections (each of 5 U) could be administered in up to three specific muscle areas (occipitalis, temporalis and trapezius) using a &#x02018;follow-the-pain&#x02019; strategy. Hence, the minimum/maximum total dose of onabotA per treatment cycle was 155 U into 31 sites/195 U into 39 sites; this injection pattern is hereafter referred to as the &#x02018;PREEMPT injection protocol&#x02019; [<xref ref-type="bibr" rid="CR46">46</xref>] (Sect. <xref rid="Sec9" ref-type="sec">5</xref>). Study medications were administered at 12-week intervals; patients underwent up to five treatment cycles: two with onabotA or placebo during the double-blind phase; and three with onabotA during the open-label phase [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par16">A combined total of 1384 patients were initially randomized to receive onabotA (<italic>n&#x02009;</italic>=&#x02009;688) or placebo (<italic>n&#x02009;</italic>=&#x02009;696) in the two trials [<xref ref-type="bibr" rid="CR40">40</xref>]. The majority of participants were female (86%) and Caucasian (90%); they had an average of 20 headache days per month at baseline [<xref ref-type="bibr" rid="CR40">40</xref>]. Approximately two-thirds (65%) were overusing acute headache pain medications at baseline [<xref ref-type="bibr" rid="CR40">40</xref>]. Approximately two-fifths (42%) had previously tried a first-line migraine prophylactic (according to UK guidelines [<xref ref-type="bibr" rid="CR15">15</xref>]) [<xref ref-type="bibr" rid="CR37">37</xref>]; approximately one-third (35%) had previously failed to respond to&#x02009;&#x02265;&#x02009;3 preventative therapies [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par17">Patient demographics and disease characteristics at baseline were mostly balanced between the treatment groups in the individual studies [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In PREEMPT 1, however, patients allocated to onabotA had significantly fewer headache (12.3 vs 13.4 per month; <italic>p&#x02009;</italic>=&#x02009;0.023) and migraine (11.5 vs. 12.7 per month; <italic>p&#x02009;</italic>=&#x02009;0.006) episodes than those assigned to placebo, and significantly more cumulative hours of headache on headache days (295.7 vs. 274.9&#x000a0;h; <italic>p&#x02009;</italic>=&#x02009;0.022) [<xref ref-type="bibr" rid="CR38">38</xref>]. These between-group differences were reflected in the pooled analyses of the two trials [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><sec id="Sec5" sec-type="results"><title>Results</title><p id="Par18">Key findings from the 24-week, double-blind phases of PREEMPT 1 and 2 are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Notably, both studies were characterized by a large placebo response [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]; onabotA achieved a statistically significant improvement versus placebo for the primary endpoint in PREEMPT 2 (mean change from baseline to week 24 in the monthly frequency of headache days), but not the primary endpoint in PREEMPT 1 (mean change from baseline to week 24 in the monthly frequency of headache episodes) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR38">38</xref>].<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Efficacy of intramuscular onabotulinumtoxinA (Botox<sup>&#x000ae;</sup>) for prevention of headaches in adults with chronic migraine. Intent-to-treat results from the multicentre PREEMPT 1 [<xref ref-type="bibr" rid="CR38">38</xref>] and 2 [<xref ref-type="bibr" rid="CR39">39</xref>] studies and pooled analyses [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] of these trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="6">Week 24<sup>a</sup>
</th><th align="left" colspan="2">Week 56<sup>a</sup>
</th></tr><tr><th align="left" colspan="2">PREEMPT 1 [<xref ref-type="bibr" rid="CR38">38</xref>]</th><th align="left" colspan="2">PREEMPT 2 [<xref ref-type="bibr" rid="CR39">39</xref>]</th><th align="left" colspan="2">Pooled analysis [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]</th><th align="left" colspan="2">Pooled analysis [<xref ref-type="bibr" rid="CR41">41</xref>]</th></tr><tr><th align="left">OnabotA (<italic>n&#x02009;</italic>=&#x02009;341)</th><th align="left">PL (<italic>n&#x02009;</italic>=&#x02009;338)</th><th align="left">OnabotA (<italic>n&#x02009;</italic>=&#x02009;347)</th><th align="left">PL (<italic>n&#x02009;</italic>=&#x02009;358)</th><th align="left">OnabotA<sup>b</sup> (<italic>n&#x02009;</italic>=&#x02009;688)</th><th align="left">PL<sup>b</sup> (<italic>n&#x02009;</italic>=&#x02009;696)</th><th align="left">OnabotA&#x02009;&#x02192;&#x02009;onabotA<sup>b</sup> (<italic>n&#x02009;</italic>=&#x02009;688)</th><th align="left">PL&#x02009;&#x02192;&#x02009;onabotA<sup>b</sup> (<italic>n&#x02009;</italic>=&#x02009;696)</th></tr></thead><tbody><tr><td align="left">HA days/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;7.8**</td><td char="." align="char">&#x02212;&#x000a0;6.4</td><td char="." align="char">&#x02212;&#x000a0;9.0***<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;6.7<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;8.4***<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;6.6<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;11.7*<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;10.8<sup>d</sup>
</td></tr><tr><td align="left">Moderate to severe HA days/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;7.2**</td><td char="." align="char">&#x02212;&#x000a0;5.8</td><td char="." align="char">&#x02212;&#x000a0;8.3***</td><td char="." align="char">&#x02212;&#x000a0;5.8</td><td char="." align="char">&#x02212;&#x000a0;7.7***</td><td char="." align="char">&#x02212;&#x000a0;5.8</td><td char="." align="char">&#x02212;&#x000a0;10.7*</td><td char="." align="char">&#x02212;&#x000a0;9.9</td></tr><tr><td align="left">Cumulative h of HA on HA days/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;106.7**</td><td char="." align="char">&#x02212;&#x000a0;70.4</td><td char="." align="char">&#x02212;&#x000a0;132.4***</td><td char="." align="char">&#x02212;&#x000a0;90.0</td><td char="." align="char">&#x02212;&#x000a0;119.7***</td><td char="." align="char">&#x02212;&#x000a0;80.5</td><td char="." align="char">&#x02212;&#x000a0;169.1*</td><td char="." align="char">&#x02212;&#x000a0;145.7</td></tr><tr><td align="left">HA episodes/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;5.2<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;5.3<sup>d</sup>
</td><td char="." align="char">&#x02212;&#x000a0;5.3**</td><td char="." align="char">&#x02212;&#x000a0;4.6</td><td char="." align="char">&#x02212;&#x000a0;5.2**</td><td char="." align="char">&#x02212;&#x000a0;4.9</td><td char="." align="char">&#x02212;&#x000a0;7.4</td><td char="." align="char">&#x02212;&#x000a0;7.5</td></tr><tr><td align="left">Migraine days/month<sup>c,e</sup>
</td><td char="." align="char">&#x02212;&#x000a0;7.6**</td><td char="." align="char">&#x02212;&#x000a0;6.1</td><td char="." align="char">&#x02212;&#x000a0;8.7***</td><td char="." align="char">&#x02212;&#x000a0;6.3</td><td char="." align="char">&#x02212;&#x000a0;8.2***</td><td char="." align="char">&#x02212;&#x000a0;6.2</td><td char="." align="char">&#x02212;&#x000a0;11.2*</td><td char="." align="char">&#x02212;&#x000a0;10.3</td></tr><tr><td align="left">Migraine episodes/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;4.8</td><td char="." align="char">&#x02212;&#x000a0;4.9</td><td char="." align="char">&#x02212;&#x000a0;4.9**<sup>f</sup>
</td><td char="." align="char">&#x02212;&#x000a0;4.2<sup>f</sup>
</td><td char="." align="char">&#x02212;&#x000a0;4.9**</td><td char="." align="char">&#x02212;&#x000a0;4.5</td><td char="." align="char">&#x02212;&#x000a0;6.8</td><td char="." align="char">&#x02212;&#x000a0;7.0</td></tr><tr><td align="left">Acute HA pain medication intakes/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;10.3</td><td char="." align="char">&#x02212;&#x000a0;10.4</td><td char="." align="char">&#x02212;&#x000a0;9.9</td><td char="." align="char">&#x02212;&#x000a0;8.4</td><td char="." align="char">&#x02212;&#x000a0;10.1</td><td char="." align="char">&#x02212;&#x000a0;9.4</td><td char="." align="char">&#x02212;&#x000a0;15.4</td><td char="." align="char">&#x02212;&#x000a0;15.7</td></tr><tr><td align="left">Acute HA pain medication intake days/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;5.7<sup>f</sup>
</td><td char="." align="char">&#x02212;&#x000a0;5.8<sup>f</sup>
</td><td char="." align="char">&#x02212;&#x000a0;6.4***<sup>f</sup>
</td><td char="." align="char">&#x02212;&#x000a0;4.8<sup>f</sup>
</td><td char="." align="char">&#x02212;&#x000a0;6.1*</td><td char="." align="char">&#x02212;&#x000a0;5.3</td><td char="." align="char">&#x02212;&#x000a0;8.4</td><td char="." align="char">&#x02212;&#x000a0;8.5</td></tr><tr><td align="left">Triptan medication intakes/month<sup>c</sup>
</td><td char="." align="char">&#x02212;&#x000a0;3.3*</td><td char="." align="char">&#x02212;&#x000a0;2.5</td><td char="." align="char">&#x02212;&#x000a0;3.0***</td><td char="." align="char">&#x02212;&#x000a0;1.7</td><td char="." align="char">&#x02212;&#x000a0;3.2***</td><td char="." align="char">&#x02212;&#x000a0;2.1</td><td char="." align="char">&#x02212;&#x000a0;4.2</td><td char="." align="char">&#x02212;&#x000a0;3.8</td></tr><tr><td align="left">HIT-6 score<sup>c,g</sup>
</td><td char="." align="char">&#x02212;&#x000a0;4.7***</td><td char="." align="char">&#x02212;&#x000a0;2.4</td><td char="." align="char">&#x02212;&#x000a0;4.9***</td><td char="." align="char">&#x02212;&#x000a0;2.4</td><td char="." align="char">&#x02212;&#x000a0;4.8***</td><td char="." align="char">&#x02013;&#x000a0;2.4</td><td char="." align="char">&#x02212;&#x000a0;7.7</td><td char="." align="char">&#x02212;&#x000a0;7.0</td></tr><tr><td align="left">Pts with severe HIT-6 score<sup>g</sup> (%)</td><td char="." align="char">68.9***</td><td char="." align="char">79.9</td><td char="." align="char">66.3**</td><td char="." align="char">76.5</td><td char="." align="char">67.6***</td><td char="." align="char">78.2</td><td char="." align="char">50.6</td><td char="." align="char">51.9</td></tr><tr><td align="left">MSQ RR subscale score<sup>c,h</sup>
</td><td char="." align="char">16.8***<sup>f</sup>
</td><td char="." align="char">8.8<sup>f</sup>
</td><td char="." align="char">17.2***<sup>f</sup>
</td><td char="." align="char">8.4<sup>f</sup>
</td><td char="." align="char">17.0***</td><td char="." align="char">8.6</td><td char="." align="char">25.2*</td><td char="." align="char">21.8</td></tr><tr><td align="left">MSQ RP subscale score<sup>c,h</sup>
</td><td char="." align="char">12.6**<sup>f</sup>
</td><td char="." align="char">7.6<sup>f</sup>
</td><td char="." align="char">13.5***<sup>f</sup>
</td><td char="." align="char">5.4<sup>f</sup>
</td><td char="." align="char">13.1***</td><td char="." align="char">6.4</td><td char="." align="char">19.0</td><td char="." align="char">17.3</td></tr><tr><td align="left">MSQ EF subscale score<sup>c,h</sup>
</td><td char="." align="char">16.9***<sup>f</sup>
</td><td char="." align="char">10.0<sup>f</sup>
</td><td char="." align="char">19.0***<sup>f</sup>
</td><td char="." align="char">9.1<sup>f</sup>
</td><td char="." align="char">17.9***</td><td char="." align="char">9.5</td><td char="." align="char">25.0</td><td char="." align="char">22.1</td></tr></tbody></table><table-wrap-foot><p>
<italic>EF</italic> emotional functioning, <italic>HA</italic> headache, <italic>HIT-6</italic> Headache Impact Test-6, <italic>MID</italic> minimal important difference, <italic>MSQ</italic> Migraine-Specific Quality-of-Life Questionnaire (v2.1), <italic>OnabotA</italic> onabotulinumtoxinA, <italic>PL</italic> placebo, <italic>pts</italic> patients, <italic>RP</italic> role preventive, <italic>RR</italic> role restrictive</p><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x02264;&#x02009;0.001 vs (corresponding) PL</p><p>
<sup>a</sup>Results at week 24 (end of the double-blind phase) and week 56 (end of the open-label phase) were assessed over a 4-week period ending at week 24 and week 56, respectively</p><p>
<sup>b</sup>Of the 688 pts originally randomized to onabotA in the double-blind phase, 607 entered the open-label phase (and continued to receive onabotA). Of the 696 pts originally randomized to PL in the double-blind phase, 629 entered the open-label phase (and crossed over to receive onabotA)</p><p>
<sup>c</sup>Mean change from baseline (week 0) (values at baseline were assessed over the prior 4-week period)</p><p>
<sup>d</sup>Primary efficacy endpoint</p><p>
<sup>e</sup>Definite or probable migraine days or episodes</p><p>
<sup>f</sup>Data derived from the Medicines and Healthcare Products Regulatory Agency UK public assessment report [<xref ref-type="bibr" rid="CR37">37</xref>]</p><p>
<sup>g</sup>Score of&#x02009;&#x02265;&#x02009;60 indicates a severe impact. The established clinically meaningful MID (between-group) is 2.3; the established clinically meaningful MID from baseline (within-group) is &#x02212;&#x000a0;5</p><p>
<sup>h</sup>On a 0&#x02013;100 scale, with higher scores indicating better health-related quality of life. The established clinically meaningful MIDs (between-group) are 3.2, 4.6 and 7.5 for the RR, RP and EF subscales, respectively; the established clinically meaningful MIDs from baseline (within-group) are 10.9, 8.3 and 12.2 for the RR, RP and EF subscales, respectively</p></table-wrap-foot></table-wrap>
</p><p id="Par19">According to a pooled analysis of the two trials, the mean decrease from baseline to week 24 in the monthly frequency of headache days (the primary endpoint) significantly favoured onabotA over placebo (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR40">40</xref>]. Indeed, based on pooled data, mean changes from baseline in the monthly frequency of headache days, moderate to severe headache days, severe headache days, headache episodes, migraine days and migraine episodes significantly (<italic>p&#x02009;</italic>&#x02264;&#x02009;0.027) favoured onabotA over placebo at all time points through week 24, as did the monthly cumulative hours of headache on headache days [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par20">Other pooled analyses indicated that, at week 24, significantly (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001) more onabotA than placebo recipients demonstrated a clinically meaningful&#x02009;&#x02265;&#x02009;50% decrease from baseline in the monthly frequency of headache days (47.1 vs. 35.1%), moderate to severe headache days (49.4 vs. 37.5%) and migraine days (48.2 vs. 36.4%) as well as in the monthly cumulative hours of headache on headache days (50.3 vs. 38.9%) [<xref ref-type="bibr" rid="CR41">41</xref>]; additionally, significantly (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001) more onabotA recipients experienced an improvement in headache-day severity [i.e.&#x02009;&#x02265;&#x02009;1-grade improvement from baseline in Average Daily Headache Severity (ADHS) score: 35.8 vs. 23.1%] [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par21">Moreover, a pooled subgroup analysis [<xref ref-type="bibr" rid="CR43">43</xref>] indicated that patients who experienced an inadequate reduction in headache-day frequency nonetheless experienced a reduction in headache-day severity. Specifically, in the subset of patients who demonstrated a&#x02009;&#x0003c;&#x02009;50% decrease from baseline in the monthly frequency of headache days (<italic>n&#x02009;</italic>=&#x02009;645), the mean decrease from baseline to week 24 in the monthly frequency of severe headache days significantly (<italic>p&#x02009;</italic>=&#x02009;0.001) favoured onabotA over placebo (1.8 vs. 0.4), as did the proportion of severe headache days per month (30.3 vs. 35.5%); significantly (<italic>p&#x02009;</italic>=&#x02009;0.01) more onabotA recipients experienced a&#x02009;&#x02265;&#x02009;1-grade improvement from baseline in ADHS score (41.1 vs. 31.4%; <italic>p&#x02009;</italic>=&#x02009;0.01) [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par22">In other pooled subgroup analyses, statistically significant (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.05) reductions in all headache symptoms favouring onabotA over placebo were seen among patients who were medication overusers at baseline [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] and those who had previously tried a first-line migraine prevention medication [<xref ref-type="bibr" rid="CR37">37</xref>]. Generally similar results were seen among patients who were not medication overusers at baseline [<xref ref-type="bibr" rid="CR44">44</xref>] or had not previously tried a first-line prophylactic medication [<xref ref-type="bibr" rid="CR37">37</xref>]. Among patients who had previously failed to respond to&#x02009;&#x02265;&#x02009;3 preventative therapies, the reduction from baseline in the monthly frequency of headache days was significantly greater among onabotA recipients (<italic>n&#x02009;</italic>=&#x02009;231) compared with placebo recipients (<italic>n&#x02009;</italic>=&#x02009;248) [7.4 vs. 4.7&#x000a0;days; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001] [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par23">As regards assessments of acute medication use, onabotA therapy was associated with significant reductions in the number of acute headache pain medication intake days per month and as well as in the monthly frequency of triptan intakes, based on pooled PREEMPT data (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par24">OnabotA therapy was also associated with a significant reduction in headache impact, as assessed using the Headache Impact Test-6 (HIT-6), and a significant improvement in HR-QOL, as assessed using the Migraine Specific Quality of Life Questionnaire (MSQ), based on pooled PREEMPT data (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Specifically, statistically significant and clinically meaningful reductions in total HIT-6 score favouring onabotA over placebo were seen at all assessments from week 16 through week 24, while statistically significant and clinically meaningful improvements in all three MSQ domain scores favouring onabotA over placebo were seen at both time points assessed, namely week 12 and week 24 [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. In pooled subgroup analyses, statistically significant and clinically important reductions in headache impact and improvements in HR-QOL favouring onabotA over placebo were seen regardless of whether or not patients were medication overusers [<xref ref-type="bibr" rid="CR48">48</xref>] and, in general, irrespective of whether or not they had received prior first-line prophylactics [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par25">Based on pooled analyses, all assessments of headache symptoms, acute medication use, headache impact and HR-QOL continued to improve relative to baseline during the 32-week, open-label extension phase (when all patients were treated with onabotA), both in patients who had previously received onabotA during the double-blind phase (&#x02018;onabotA-only group&#x02019;) and those who had previously received placebo (&#x02018;placebo/onabotA group&#x02019;) [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR50">50</xref>] (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Significant improvements from baseline to week 56 were observed for all of these assessments, both in the onabotA-only group and the onabotA/placebo group [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. However, some assessments of headache symptoms (e.g. headache-day frequency) and HR-QOL (i.e. the MSQ role restrictive domain) still significantly favoured the onabotA-only group over the onabotA/placebo group at the end of the open-label phase (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. A pooled subgroup analysis of patients who completed all five treatment cycles (<italic>n&#x02009;</italic>=&#x02009;513 and 492 in the onabotA-only and placebo/onabotA groups, respectively) yielded mostly similar results, further supporting the suggestion that, at week 56, patients who started onabotA therapy earlier in these trials had better outcomes than those who began therapy later [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par26">Importantly, a post hoc pooled analysis provided evidence that a meaningful proportion of patients who did not respond after the first onabotA treatment cycle did respond after the second or third cycle [<xref ref-type="bibr" rid="CR52">52</xref>]. In terms of achieving a&#x02009;&#x02265;&#x02009;50% decrease from baseline in the monthly frequency of headache days, 78 (22%) of the 349 onabotA-treated patients who did not reach this endpoint after the first cycle did demonstrate a&#x02009;&#x02265;&#x02009;50% decrease after the second cycle (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Furthermore, 71 (26%) of the 271 onabotA-treated patients who did not demonstrate a&#x02009;&#x02265;&#x02009;50% decrease in the monthly frequency of headache days after the first and second cycles did reach this endpoint after the third cycle (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Similar results were seen for other key outcomes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR52">52</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Proportion of onabotulinumtoxinA-treated patients who responded (with a&#x02009;&#x02265;&#x02009;50% improvement from baseline in the headache symptom or impact assessment indicated) for the first time after treatment cycles 1, 2 and 3 in the pooled PREEMPT trials [<xref ref-type="bibr" rid="CR52">52</xref>]. For each assessment, the maximum possible number of first-time responders in the cycle indicated is shown above the bar. <italic>HA</italic> headache, <italic>HIT</italic>-6 Headache Impact Test-6</p></caption><graphic xlink:href="40265_2018_894_Fig1_HTML" id="MO1"/></fig>
</p></sec></sec><sec id="Sec6"><title>COMPEL Study</title><p id="Par27">In the multinational, open-label COMPEL study [<xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref>], adults with CM (ICHD-2 criteria [<xref ref-type="bibr" rid="CR45">45</xref>]) received up to nine onabotA treatment cycles (155 U/12-week cycle; administered as per the PREEMPT injection protocol); the design of this study is described in detail elsewhere [<xref ref-type="bibr" rid="CR54">54</xref>]. Consistent with the PREEMPT studies, most of the 715 evaluable participants were female (85%) and Caucasian (81%); they reported an average of 22 headache days per month at baseline. Just over one-half (52.1%) completed all nine treatment cycles (108&#x000a0;weeks) [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par28">Clinical benefits persisted during long-term (2&#x000a0;years) onabotA therapy. Regarding the monthly frequency of headache days, there was a significant reduction relative to baseline at week 108 (&#x02212;10.7&#x000a0;days; <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.0001) [primary outcome]; sequential improvements were seen at all earlier assessments [&#x02212;&#x02009;7.4, &#x02212;9.2 and &#x02212;&#x02009;9.8&#x000a0;days after 2, 5 and 7 cycles (24, 60 and 84&#x000a0;weeks), respectively; all <italic>p&#x02009;</italic>&#x0003c;&#x02009;0.0001 vs. baseline] [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par29">Assessments of headache impact (total HIT-6 score) [<xref ref-type="bibr" rid="CR53">53</xref>], migraine-related disability (Migraine Disability Assessment Questionnaire) [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], HR-QOL (all three MSQ domain scores) [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], sleep disturbance (Pittsburgh Sleep Quality Index) [<xref ref-type="bibr" rid="CR58">58</xref>], fatigue (Fatigue Severity Scale) [<xref ref-type="bibr" rid="CR58">58</xref>], depression (9-item Patient Health Questionnaire) [<xref ref-type="bibr" rid="CR59">59</xref>] and anxiety (7-item Generalized Anxiety Disorder Assessment) [<xref ref-type="bibr" rid="CR59">59</xref>] were also significantly (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.0001) improved from baseline at week 108; similar improvements were seen at all earlier assessments [<xref ref-type="bibr" rid="CR56">56</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par30">Consistent with the overall study population, significant (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.0001 vs. baseline) improvements in headache frequency, migraine-related disability and HR-QOL assessments were seen at all time points in subgroup analyses of patients with headaches every day [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>] or allodynia [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR62">62</xref>] at baseline.</p><p id="Par31">Despite differences in study design, the patient population in COMPEL was, as noted above, similar to that in the PREEMPT trials, and outcomes at week 24 were generally consistent, based on a descriptive comparison of COMPEL and pooled PREEMPT data [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="Sec7"><title>Real-World Studies</title><p id="Par32">From among the many investigations that have demonstrated the effectiveness of onabotA as a preventative therapy for CM in real-world clinical practice in Europe, this section focuses on findings from four prospective, observational studies that each enrolled&#x02009;&#x0003e;&#x02009;150 patients at one or more treatment centres throughout the region [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par33">Of note, the post-authorization REPOSE study is the only one of these trials to have been conducted across multiple countries [<xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR72">72</xref>]. Briefly, among 641 patients enrolled at 78 centres in Germany, Italy, Norway, Russia, Spain, Sweden and the UK, 633 (85% of whom were women) received at least one onabotA dose for a total of 3499 treatment sessions over a period of 2&#x000a0;years [<xref ref-type="bibr" rid="CR72">72</xref>]. OnabotA was administered at&#x02009;&#x02248;&#x02009;3-month intervals as per the physician&#x02019;s usual practice, guided by the summary of product characteristics; the majority of treatment sessions were consistent with the PREEMPT protocol [<xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par34">Consistent with the results of clinical trials (PREEMPT and COMPEL), onabotA therapy significantly (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001) reduced the mean monthly frequency of headache days relative to baseline; sequential improvements were seen at all assessments (e.g. &#x02212;&#x02009;8.2, &#x02212;&#x02009;9.1, &#x02212;&#x02009;11.4, &#x02212;&#x02009;13.0 and &#x02212;&#x02009;13.3&#x000a0;days after 1, 2, 4, 6 and 8 cycles, respectively) [<xref ref-type="bibr" rid="CR72">72</xref>]. Regarding HR-QOL, all three MSQ domain scores increased significantly (<italic>p&#x02009;</italic>&#x0003c;&#x02009;0.001) from baseline at both time points assessed, namely after cycle 2 and cycle 8 [<xref ref-type="bibr" rid="CR72">72</xref>]. Similar improvements in headache symptoms and HR-QOL (based on MSQ and EQ-5D total scores) were seen in both the 6-month [<xref ref-type="bibr" rid="CR70">70</xref>] and 1-year [<xref ref-type="bibr" rid="CR71">71</xref>] REPOSE study interim analyses.</p><p id="Par35">Patients enrolled in the remaining studies (from single centres in Italy [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] and the UK [<xref ref-type="bibr" rid="CR65">65</xref>&#x02013;<xref ref-type="bibr" rid="CR69">69</xref>] or from 13 centres in Spain [<xref ref-type="bibr" rid="CR73">73</xref>]) had failed to respond to or were intolerant of&#x02009;&#x02265;&#x02009;1 oral preventative therapy [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]; around one-half [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR73">73</xref>] or all [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] of them fulfilled criteria for medication overuse [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR73">73</xref>] or had comorbid MOH [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] at baseline. The majority (78&#x02013;86%) were women [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par36">Prophylactic treatment with onabotA administered in accordance with the PREEMPT protocol significantly (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. baseline) improved a range of headache symptom and impact measures, as assessed after, for example, 1 cycle [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR73">73</xref>] or 1 [<xref ref-type="bibr" rid="CR73">73</xref>] or 2 [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] years of treatment. Similar to REPOSE [<xref ref-type="bibr" rid="CR72">72</xref>], these assessments showed progressive improvements during 1 [<xref ref-type="bibr" rid="CR73">73</xref>] or 2 [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>] years of therapy.</p><p id="Par37">An updated and expanded analysis from the UK study [<xref ref-type="bibr" rid="CR68">68</xref>] (<italic>n&#x02009;</italic>=&#x02009;434 vs. 254 [<xref ref-type="bibr" rid="CR65">65</xref>]) showed that onabotA was equally effective in patients with or without medication overuse at baseline. In terms of achieving a clinically meaningful response, 32% of patients reported a&#x02009;&#x02265;&#x02009;50% reduction in headache-day frequency (PREEMPT criteria), 47% reported a&#x02009;&#x02265;&#x02009;30% reduction in headache-day frequency [National Institute for Health and Care Excellence (NICE) criteria] and 66% reported a&#x02009;&#x02265;&#x02009;50% reduction in headache- or migraine- day frequency or an increase in headache-free days twice that of baseline (Hull Headache Clinic criteria) after the first treatment cycle [<xref ref-type="bibr" rid="CR65">65</xref>]. Another updated and expanded analysis of this study [<xref ref-type="bibr" rid="CR69">69</xref>] (<italic>n&#x02009;</italic>=&#x02009;536) showed that patients with or without medication overuse responded equally well to the first treatment cycle.</p><p id="Par38">Interesting information on long-term outcomes in patients achieving a clinically meaningful response is also available from the UK study [<xref ref-type="bibr" rid="CR67">67</xref>]. Patients who were responders after two cycles (NICE or Hull criteria) and continued to a third cycle were allowed to stop therapy if they experienced&#x02009;&#x0003c;&#x02009;10 headache days per month for 3 consecutive months (Hull modified positive stopping rule); 56 (61.5%) of 91 initial responders who were able to successfully stop therapy within 2&#x000a0;years continued to show a sustained response. However, 17 (19%) patients relapsed and restarted therapy; overall 84 (48%) of 175 initial responders were still receiving onabotA at 2&#x000a0;years. Of note, 11 (12%) of 91 patients became resistant and reverted to CM while still receiving onabotA [<xref ref-type="bibr" rid="CR67">67</xref>].</p></sec></sec><sec id="Sec8"><title>Tolerability of OnabotulinumtoxinA</title><p id="Par39">Repeated injection of onabotA (155&#x02013;195 U) every 12&#x000a0;weeks for up to five cycles was generally well tolerated in the PREEMPT clinical trial programme discussed in Sect. <xref rid="Sec4" ref-type="sec">3.1</xref> [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. OnabotA recipients mostly reported adverse events (AEs) that were mild or moderate in severity and resolved without sequelae; they infrequently discontinued therapy due to AEs [3.8 (vs. 1.2% of placebo recipients) during the double-blind phase of the pooled PREEMPT studies; 2.6% during the open-label extension phase of the pooled PREEMPT studies] [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par40">Moreover, treatment-related AEs (TRAEs) were consistent with the known tolerability profile of onabotA when injected into head and neck muscles; no new safety events were observed [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. The overall rates of TRAEs were 29.4% for patients receiving two cycles of onabotA during the double-blind phase (<italic>n&#x02009;</italic>=&#x02009;687) [vs. 12.7% for placebo (<italic>n&#x02009;</italic>=&#x02009;692)] [<xref ref-type="bibr" rid="CR40">40</xref>] and 34.8% for patients receiving all five cycles of onabotA during the double-blind and open-label extension phases (<italic>n&#x02009;</italic>=&#x02009;515) [<xref ref-type="bibr" rid="CR51">51</xref>]. Of note, the rate of TRAEs decreased progressively with each subsequent treatment session, being 48.3, 37.2, 37.8, 26.3 and 19.1% after the first, second, third, fourth and fifth cycles of onabotA, respectively [<xref ref-type="bibr" rid="CR51">51</xref>]. The most commonly observed TRAEs in patients receiving onabotA included neck pain [6.7 (vs. 2.2% with placebo) during the double-blind phase; 4.6% during the open-label extension phase of the pooled PREEMPT studies], muscle weakness [5.5 (vs. 0.3%); 3.9%], eyelid ptosis [3.3 (vs. 0.3%); 2.5%], injection-site pain [3.2 (vs. 2.0%); 2.0%] and musculoskeletal pain [2.2 (vs. 0.7%); 1.1%] [<xref ref-type="bibr" rid="CR41">41</xref>]. Facial paresis accounted for two-fifths of the reports of muscle weakness during the double-blind phase (incidence of 2.2%) and for nearly one-third of the reports of muscle weakness during the open-label extension phase (incidence of 1.2%) [<xref ref-type="bibr" rid="CR41">41</xref>]. Only one onabotA recipient in the pooled PREEMPT studies experienced a serious TRAE (migraine requiring hospitalization) [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par41">Design differences notwithstanding, tolerability findings from the PREEMPT trials are supported and extended by those of the long-term, open-label COMPEL study [<xref ref-type="bibr" rid="CR53">53</xref>] (Sect. <xref rid="Sec6" ref-type="sec">3.2</xref>) and, where reported, several real-world studies [<xref ref-type="bibr" rid="CR63">63</xref>&#x02013;<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>] (Sect. <xref rid="Sec7" ref-type="sec">3.3</xref>). In COMPEL, for example, the overall rate of TRAEs was 15.0% at week 24 [<xref ref-type="bibr" rid="CR55">55</xref>] and 18.3% at week 108 [<xref ref-type="bibr" rid="CR53">53</xref>]. The most frequently reported TRAE was neck pain, both at week 24 (occurring in 2.9% of patients) [<xref ref-type="bibr" rid="CR55">55</xref>] and week 108 (4.1%) [<xref ref-type="bibr" rid="CR53">53</xref>]. As in the PREEMPT programme, only one patient in COMPEL reported a serious TRAE (rash); no novel safety signals were seen [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par42">To date, the largest completed study to evaluate the safety of onabotA for the preventative treatment of CM in routine clinical practice has been a prospective, observational, multinational, post-authorization study (hereafter referred to as &#x02018;CM-PASS&#x02019;) [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Briefly, the study population consisted of 1160 patients (84% women; 98% Caucasian) enrolled at 58 centres across Germany, Spain, Sweden and the UK. The majority (86%) had a diagnosis of CM or transformed (i.e. chronified) migraine at baseline; approximately one-quarter (24.7%) were medication overusers. Almost one-half (43.9%) were receiving&#x02009;&#x02265;&#x02009;1 acute and&#x02009;&#x02265;&#x02009;1 preventative therapy at baseline; approximately one-half (51%) had previously received onabotA for CM [<xref ref-type="bibr" rid="CR74">74</xref>]. Participating physicians were provided with the summary of product characteristics, but were not mandated to follow the PREEMPT injection protocol set out therein. Most (90.1%) patients underwent&#x02009;&#x02265;&#x02009;1 treatment session that deviated from the recommended label treatment paradigm, although the median dose (155 U) and median number of injection sites (<italic>n&#x02009;</italic>=&#x02009;31) were consistent across all observed onabotA treatment sessions (<italic>n&#x02009;</italic>=&#x02009;4017) and in line with the PREEMPT protocol. The median interval between sessions was 13.7&#x000a0;weeks [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par43">Over a period of 64&#x000a0;weeks, one-quarter (25.1%) of CM-PASS participants reported&#x02009;&#x02265;&#x02009;1 TRAE, most frequently neck pain (4.4%) and eyelid ptosis (4.1%). TRAEs of special interest included worsening of migraine (4.0%), intractable migraine (0.4%) and dysphagia (0.3%) [<xref ref-type="bibr" rid="CR74">74</xref>]; the incidence rates of intractable migraine and dysphagia (secondary and primary outcome measures, respectively) were 1.6 and 0.4 per 1000 person-months [<xref ref-type="bibr" rid="CR75">75</xref>]. As in the PREEMPT and COMPEL studies, only one patient reported a serious TRAE (worsening of migraine) [<xref ref-type="bibr" rid="CR74">74</xref>]. Of note, approximately three-quarters (74.4%) of 1090 evaluable patients indicated they were satisfied/extremely satisfied with onabotA therapy; this included, respectively, 83 and 65% of patients who had and had not previously received onabotA [<xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec9"><title>Dosage and Administration of OnabotulinumtoxinA</title><p id="Par44">In the EU, onabotA has been approved for the prevention of headaches in adults with CM through the mutual recognition procedure, with Ireland as the reference state [<xref ref-type="bibr" rid="CR18">18</xref>]. However, the exact wording of the indication may vary between member states, and local prescribing information should be consulted for specific details.</p><p id="Par45">As per the PREEMPT clinical protocol, the recommended dose of onabotA is 155&#x02013;195 U administered intramuscularly as 0.1&#x000a0;mL (5 U) injections to 31 and up to 39 sites across seven specific head/neck muscle areas as follows: corrugator [10 U (2 sites)]; procerus [5 U (1 site)]; frontalis [20 U (4 sites)]; temporalis [40 U (8 sites) up to 50 U (up to 10 sites)]; occipitalis [30 U (6 sites) up to 40 U (up to 8 sites)]; cervical paraspinal muscle group [20 U (4 sites)]; and trapezius [30 U (6 sites) up to 50 U (up to 10 sites)] [<xref ref-type="bibr" rid="CR35">35</xref>]. All muscles should be injected bilaterally, with the exception of the procerus, which should be injected at one site only (midline). The recommended retreatment schedule is every 12&#x000a0;weeks [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par46">Local prescribing information should be consulted for full details of dosage and administration guidelines, contraindications and warnings and precautions relating to the use of onabotA for the prevention of CM.</p></sec><sec id="Sec10"><title>Place of OnabotulinumtoxinA in the Prevention of Chronic Migraine</title><p id="Par47">The pivotal PREEMPT programme showed that treatment with up to five cycles of onabotA (155&#x02013;195 U/cycle) at 12-week intervals was generally well tolerated (Sect. <xref rid="Sec8" ref-type="sec">4</xref>) and effective in reducing headache symptoms, headache impact and acute headache pain medication usage, as well as improving HR-QOL, in patients with CM, approximately two-thirds of whom were medication overusers and approximately one-third of whom had failed to respond to&#x02009;&#x02265;&#x02009;3 prior preventative therapies (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>). Improvements in headache symptoms, headache impact and HR-QOL favouring onabotA over placebo were seen regardless of whether or not patients were medication overusers and, in general, irrespective of whether or not they had received prior first-line prophylactics (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>). Moreover, onabotA not only reduced headache-day frequency, but also headache-day severity; a reduction in headache-day severity was seen even in patients who did not experience a clinically meaningful (i.e.&#x02009;&#x02265;&#x02009;50%) reduction in headache-day frequency (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>).</p><p id="Par48">During the open-label phase, in which all patients received three cycles of onabotA, all assessments of headache symptoms, acute medication usage, headache impact and HR-QOL continued to improve relative to baseline (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>). Further evidence of the benefit over time of repeated administration of onabotA exists in the form of the observation that around one-quarter of those patients who did not achieve a clinically meaningful (i.e.&#x02009;&#x02265;&#x02009;50%) reduction in headache symptoms after the first treatment cycle did respond after the second cycle, while approximately one-third of those patients who did not achieve a clinically meaningful reduction in headache impact after the first treatment cycle did respond after the second cycle (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>). Moreover, around one-quarter of those patients who did not respond in terms of these endpoints after the first and second cycles did respond after the third cycle (Sect. <xref rid="Sec4" ref-type="sec">3.1</xref>). This suggests, therefore, that in practice at least two to three cycles of onabotA should be attempted before categorizing those patients who do not respond initially as nonresponders [<xref ref-type="bibr" rid="CR52">52</xref>].</p><p id="Par49">Debate surrounding the PREEMPT studies has centred on the small treatment effect of onabotA relative to placebo, the possibility that blinding was inadequate and the relevance of the evaluated population [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The totality of data from the PREEMPT programme has, nonetheless, led to onabotA becoming the first (and so far only) headache prophylactic therapy to be specifically approved for CM in the UK (Sect. <xref rid="Sec1" ref-type="sec">1</xref>). Importantly, results from the PREEMPT programme are specific to onabotA and cannot be extrapolated to other commercially available formulations of botulinum toxin A, namely abobotulinumtoxinA (Dysport&#x02122;) and incobotulinumtoxinA (Xeomin<sup>&#x000ae;</sup>).</p><p id="Par50">The current European Federation of Neurological Societies guideline on the pharmacological treatment of migraine predates the approval of onabotA and does not mention the drug [<xref ref-type="bibr" rid="CR16">16</xref>]. As regards national guidelines, onabotA has a level 1 (highest) recommendation for the preventive treatment of CM in Italy [<xref ref-type="bibr" rid="CR76">76</xref>]. In the UK, both NICE [<xref ref-type="bibr" rid="CR47">47</xref>] and the Scottish Medicines Consortium [<xref ref-type="bibr" rid="CR77">77</xref>] recommend that onabotA be reserved for patients with CM (i.e. headaches on&#x02009;&#x02265;&#x02009;15&#x000a0;days per month of which&#x02009;&#x02265;&#x02009;8&#x000a0;days meet the criteria for migraine) who have failed to respond to&#x02009;&#x02265;&#x02009;3 prior preventative therapies and whose condition is appropriately managed for medication overuse.</p><p id="Par51">Key findings for onabotA over a period of 1&#x000a0;year in the PREEMPT programme have been substantiated and extended by the results of a 2-year clinical study (COMPEL; Sect. <xref rid="Sec6" ref-type="sec">3.2</xref>) and several large real-world studies from Europe, including REPOSE (Sect. <xref rid="Sec7" ref-type="sec">3.3</xref>) and CM-PASS (Sect. <xref rid="Sec8" ref-type="sec">4</xref>). These studies have generally enrolled patients similar to those who participated in PREEMPT and have variously confirmed the efficacy and safety of short and longer-term prevention with onabotA administered as per the PREEMPT protocol or, in the case of the multinational REPOSE [<xref ref-type="bibr" rid="CR74">74</xref>] and CM-PASS [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>] studies, largely administered in line with this injection paradigm. In COMPEL, sustained benefits were seen in patients who received up to nine treatment cycles (Sect. <xref rid="Sec6" ref-type="sec">3.2</xref>), while in real-world studies, benefits have been seen in patients who have failed to respond to or are intolerant of prior oral preventative therapies, including those with concomitant medication overuse or comorbid MOH (Sect. <xref rid="Sec7" ref-type="sec">3.3</xref>). In addition, a small real-world from Europe [<xref ref-type="bibr" rid="CR80">80</xref>] has reported a delayed and progressively beneficial effect among patients who continue to receive treatment after failing to respond to the first cycle; this supports the notion that at least another one to two cycles should be attempted before deeming those individuals who do not respond initially to be nonresponders [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par52">Data are also emerging from real-world studies that address current areas of uncertainty surrounding the use of onabotA for the prevention of CM, including how to identify patients who are more (or less) likely to respond, the appropriate duration of therapy in responders, the rate of sustained benefit in patients who successfully stop therapy (positive stopping rule), and the rate of relapse in patients who stop therapy. Duration of disease [<xref ref-type="bibr" rid="CR73">73</xref>], unilaterality of pain [<xref ref-type="bibr" rid="CR73">73</xref>], intensity of headache [<xref ref-type="bibr" rid="CR73">73</xref>], interictal CGRP levels [<xref ref-type="bibr" rid="CR82">82</xref>] and (in women) polymorphisms in genes encoding CGRP [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>] and TRPV1 [<xref ref-type="bibr" rid="CR84">84</xref>] are among the potential predictors of efficacy that have been identified, based on data collected from clinical practice in Spain [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>] and the UK [<xref ref-type="bibr" rid="CR85">85</xref>]. Among actual responders, the pattern of response appeared to be predictive of longer-term outcome [<xref ref-type="bibr" rid="CR66">66</xref>]. Based on 2&#x000a0;years&#x02019; follow-up at one UK centre [<xref ref-type="bibr" rid="CR67">67</xref>], nearly two-thirds of patients who successfully stopped therapy showed sustained benefit, while approximately one-fifth relapsed. Overall, approximately one-half of initial responders were still receiving therapy at 2&#x000a0;years (Sect. <xref rid="Sec7" ref-type="sec">3.3</xref>). Issues relevant to optimizing the long-term management of CM with onabotA in real-world clinical practice, such as when to initiate therapy and how to define (and appropriately treat) responders and nonresponders, are discussed in more detail elsewhere [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par53">On the basis of pharmacoeconomic analyses that incorporate data from the PREEMPT trials, the use of onabotA for the prevention of CM can be considered cost-effective from the perspective of the National Health Service in Italy [<xref ref-type="bibr" rid="CR86">86</xref>] and the UK [<xref ref-type="bibr" rid="CR87">87</xref>]. The real-world cost-effectiveness of onabotA in clinical practice in Europe remains to be determined, although relevant data regarding healthcare resource utilization (HRU) are being collected as part of the multinational REPOSE study [<xref ref-type="bibr" rid="CR88">88</xref>]. In this regard, interim (1-year) data from participating centres in Germany indicated that use of onabotA not only reduced HRU (e.g. physician visits and technical investigations), but also improved work performance and disability [<xref ref-type="bibr" rid="CR88">88</xref>].</p><p id="Par54">In conclusion, the totality of evidence from clinical trials and real-world studies indicates that onabotA is an effective and generally well tolerated option for the prevention of CM that may be particularly useful for patients who have previously failed to respond to or are intolerant of commonly prescribed oral prophylactics.</p><sec id="FPar2"><title>Data Selection OntabotulinumtoxinA: 300 records identified</title><p id="Par55">
<table-wrap id="Tabb"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Duplicates removed</td><td align="left">51</td></tr><tr><td align="left">Excluded at initial screening (e.g. press releases; news reports; not relevant drug/indication)</td><td align="left">23</td></tr><tr><td align="left">Excluded during initial selection (e.g. preclinical study; reviews; case reports; not randomized trial)</td><td align="left">35</td></tr><tr><td align="left">Excluded during writing (e.g. reviews; duplicate data; small patient number; nonrandomized/phase I/II trials)</td><td align="left">110</td></tr><tr><td align="left">
<bold>Cited efficacy/tolerability articles</bold>
</td><td align="left">39</td></tr><tr><td align="left">
<bold>Cited articles not efficacy/tolerability</bold>
</td><td align="left">42</td></tr><tr><td align="left" colspan="2">Search Strategy: EMBASE, MEDLINE and PubMed from 2012 to present. Previous Adis Drug Evaluation published in 2012 was hand-searched for relevant data. Clinical trial registries/databases and websites were also searched for relevant data. Key words were Onabotulinumtoxin-A, Onabot-A, Botox, BoNT-A, AGN-191622, botulinum, onabotulinum, neurotoxin A. Records were limited to those in English language. Searches last updated 16 February 2018.</td></tr></tbody></table></table-wrap>
</p></sec></sec></body><back><fn-group><fn><p>
<bold>The manuscript was reviewed by:</bold>
<bold><italic>A. Blumenfeld,</italic></bold> The Neurology Center, Carlsbad, CA, USA; <bold><italic>H. C. Diener,</italic></bold> Medical Faculty and Department of Neurology, University Duisburg-Essen, Essen, Germany; <bold><italic>F. Freitag,</italic></bold> Department of Neurology, The Medical College of Wisconsin, Milwaukee, WI, USA; <bold><italic>K. Kollewe,</italic></bold> Department of Neurology, Movement Disorder Section, Hannover Medical School, Hannover, Germany; <bold><italic>W. Schulte-Mattler,</italic></bold> Department of Neurology, University Hospital Regensburg, Regensburg, Germany; <bold><italic>R. J. Stark,</italic></bold> Van Cleef Department of Neuroscience, Monash University, Melbourne, Australia.</p></fn><fn><p>The original version of this article was revised due to a retrospective Open Access request.</p></fn><fn><p>A correction to this article is available online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40265-018-0906-6">https://doi.org/10.1007/s40265-018-0906-6</ext-link>.</p></fn><fn><p><bold>Change history</bold></p><p>4/20/2018</p><p>The article OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine, written by James E. Frampton and Stephen Silberstein, was originally published Online First without open access. After publication in volume 78, issue 5, pages 589&#x02013;600 [funder] requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by [funder]. Further details may be found at [MedEngine webpage link].</p></fn></fn-group><ack><title>Acknowledgements</title><p>During the peer review process, the manufacturer of onabotulinumtoxinA was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.</p></ack><notes notes-type="COI-statement"><title>Compliance with Ethical Standards</title><sec id="FPar3"><title>Funding</title><p id="Par56">The preparation of this review was not supported by any external funding.</p></sec><sec id="FPar4"><title>Conflicts of interest</title><p id="Par57">James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.</p><p id="Par58">As a consultant and/or advisory panel member, Stephen Silberstein receives, or has received, honoraria from: Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Curelator, Inc.; Depomed; Dr. Reddy&#x02019;s Laboratories; eNeura Inc.; electroCore Medical, LLC; INSYS Therapeutics; Labrys Biologics; Lilly USA, LLC; Medscape, LLC; Medtronic, Inc.; Neuralieve; NINDS; Pfizer, Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.</p><p id="Par59">Additional information about this Adis Drug Review can be found at <ext-link ext-link-type="uri" xlink:href="http://www.medengine.com/Redeem/457AF0606D3C2B1C">http://www.medengine.com/Redeem/457AF0606D3C2B1C</ext-link>.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Committee of the International Headache Society (IHS)</collab></person-group><article-title>The international classification of headache disorders, 3rd edition</article-title><source>Cephalalgia</source><year>2018</year><volume>38</volume><issue>1</issue><fpage>1</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1177/0333102417738202</pub-id><pub-id pub-id-type="pmid">29368949</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Brin</surname><given-names>MF</given-names></name></person-group><article-title>Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies</article-title><source>Headache</source><year>2017</year><volume>57</volume><issue>1</issue><fpage>109</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1111/head.12999</pub-id><pub-id pub-id-type="pmid">27910097</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natoli</surname><given-names>JL</given-names></name><name><surname>Manack</surname><given-names>A</given-names></name><name><surname>Dean</surname><given-names>B</given-names></name><etal/></person-group><article-title>Global prevalence of chronic migraine: a systematic review</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2009.01941.x</pub-id><pub-id pub-id-type="pmid">19614702</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>May</surname><given-names>A</given-names></name><name><surname>Schulte</surname><given-names>LH</given-names></name></person-group><article-title>Chronic migraine: risk factors, mechanisms and treatment</article-title><source>Nat Rev Neurol</source><year>2016</year><volume>12</volume><issue>8</issue><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2016.93</pub-id><pub-id pub-id-type="pmid">27389092</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigal</surname><given-names>ME</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>Concepts and mechanisms of migraine chronification</article-title><source>Headache.</source><year>2008</year><volume>48</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00969.x</pub-id><pub-id pub-id-type="pmid">18184280</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsarava</surname><given-names>Z</given-names></name><name><surname>Buse</surname><given-names>DC</given-names></name><name><surname>Manack</surname><given-names>AN</given-names></name><etal/></person-group><article-title>Defining the differences between episodic migraine and chronic migraine</article-title><source>Curr Pain Headache Rep.</source><year>2012</year><volume>16</volume><issue>1</issue><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s11916-011-0233-z</pub-id><pub-id pub-id-type="pmid">22083262</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>AM</given-names></name><name><surname>Varon</surname><given-names>SF</given-names></name><name><surname>Wilcox</surname><given-names>TK</given-names></name><etal/></person-group><article-title>Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)</article-title><source>Cephalalgia.</source><year>2011</year><volume>31</volume><issue>3</issue><fpage>301</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1177/0333102410381145</pub-id><pub-id pub-id-type="pmid">20813784</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bigal</surname><given-names>ME</given-names></name><name><surname>Serrano</surname><given-names>D</given-names></name><name><surname>Reed</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment</article-title><source>Neurology.</source><year>2008</year><volume>71</volume><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000323925.29520.e7</pub-id><pub-id pub-id-type="pmid">18711108</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Serrano</surname><given-names>D</given-names></name><name><surname>Buse</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Improving the detection of chronic migraine: development and validation of identify chronic migraine (ID-CM)</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>3</issue><fpage>203</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1177/0333102415583982</pub-id><pub-id pub-id-type="pmid">26002700</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weatherall</surname><given-names>MW</given-names></name></person-group><article-title>The diagnosis and treatment of chronic migraine</article-title><source>Ther Adv Chronic Dis.</source><year>2015</year><volume>6</volume><issue>3</issue><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1177/2040622315579627</pub-id><pub-id pub-id-type="pmid">25954496</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun-Edelstein</surname><given-names>C</given-names></name><name><surname>Rapoport</surname><given-names>AM</given-names></name></person-group><article-title>Update on the pharmacological treatment of chronic migraine</article-title><source>Curr Pain Headache Rep.</source><year>2016</year><volume>20</volume><issue>1</issue><fpage>6</fpage><pub-id pub-id-type="doi">10.1007/s11916-015-0533-9</pub-id><pub-id pub-id-type="pmid">26728188</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starling</surname><given-names>AJ</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name></person-group><article-title>Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care</article-title><source>Mayo Clin Proc.</source><year>2015</year><volume>90</volume><issue>3</issue><fpage>408</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2015.01.010</pub-id><pub-id pub-id-type="pmid">25744118</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starling</surname><given-names>AJ</given-names></name><name><surname>Vargas</surname><given-names>BB</given-names></name></person-group><article-title>A narrative review of evidence-based preventive options for chronic migraine</article-title><source>Curr Pain Headache Rep.</source><year>2015</year><volume>19</volume><issue>10</issue><fpage>49</fpage><pub-id pub-id-type="doi">10.1007/s11916-015-0521-0</pub-id><pub-id pub-id-type="pmid">26286071</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Headaches in over 12&#x000a0;s: diagnosis and management. Clinical guideline [CG150]. 2015. <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk">https://www.nice.org.uk</ext-link>. Accessed 23 Feb 2017.</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache and medication-overuse headache: 3rd edition (1st revision) 2010. <ext-link ext-link-type="uri" xlink:href="http://www.bash.org.uk">http://www.bash.org.uk</ext-link>. Accessed 23 Feb 2017.</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>S</given-names></name><name><surname>Afra</surname><given-names>J</given-names></name><name><surname>Frese</surname><given-names>A</given-names></name><etal/></person-group><article-title>EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force</article-title><source>Eur J Neurol.</source><year>2009</year><volume>16</volume><fpage>968</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02748.x</pub-id><pub-id pub-id-type="pmid">19708964</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frampton</surname><given-names>JE</given-names></name></person-group><article-title>OnabotulinumtoxinA (BOTOX<sup>&#x000ae;</sup>): a review of its use in the prophylaxis of headaches in adults with chronic migraine</article-title><source>Drugs.</source><year>2012</year><volume>72</volume><issue>6</issue><fpage>825</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.2165/11208880-000000000-00000</pub-id><pub-id pub-id-type="pmid">22468643</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Health Products Regulatory Authority. BOTOX 50, 100, 200 Allergan Units, powder for solution for injection (BOTULINUM TOXIN TYPE A): IE/H/0113/001-003: IPAR. <ext-link ext-link-type="uri" xlink:href="http://www.hpra.ie">http://www.hpra.ie</ext-link>. Accessed 30 May 2017.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Allergan Inc. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use: US prescribing information. 2016. <ext-link ext-link-type="uri" xlink:href="http://www.allergan.com">http://www.allergan.com</ext-link>. Accessed 11 Jan 2017.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Allergan Inc. BOTOX onabotulinumtoxinA for injection Ph. Eur: Canadian product monograph. 2014. <ext-link ext-link-type="uri" xlink:href="https://allergan-web-cdn-prod.azureedge.net">https://allergan-web-cdn-prod.azureedge.net</ext-link>. Accessed 24 Feb 2017.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitcup</surname><given-names>SM</given-names></name><name><surname>Turkel</surname><given-names>CC</given-names></name><name><surname>Degryse</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Development of onabotulinumtoxinA for chronic migraine</article-title><source>Ann NY Acad Sci.</source><year>2014</year><volume>1329</volume><fpage>67</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1111/nyas.12488</pub-id><pub-id pub-id-type="pmid">25399521</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>LL</given-names></name></person-group><article-title>Identification of the major steps in botulinum toxin action</article-title><source>Ann Rev Pharmacol Toxicol.</source><year>2004</year><volume>44</volume><fpage>167</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.44.101802.121554</pub-id><pub-id pub-id-type="pmid">14744243</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: a review of the mode of action in migraine. Acta Neurol Scand. 2018. 10.1111/ane.12906.</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szok</surname><given-names>D</given-names></name><name><surname>Csati</surname><given-names>A</given-names></name><name><surname>Vecsei</surname><given-names>L</given-names></name><etal/></person-group><article-title>Treatment of chronic migraine with onabotulinumtoxinA: mode of action, efficacy and safety</article-title><source>Toxins.</source><year>2015</year><volume>7</volume><issue>7</issue><fpage>2659</fpage><lpage>2673</lpage><pub-id pub-id-type="doi">10.3390/toxins7072659</pub-id><pub-id pub-id-type="pmid">26193319</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><etal/></person-group><article-title>Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains</article-title><source>Cephalalgia.</source><year>2014</year><volume>34</volume><issue>11</issue><fpage>853</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1177/0333102414527648</pub-id><pub-id pub-id-type="pmid">24694964</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name><etal/></person-group><article-title>Origin of pain in migraine: evidence for peripheral sensitization</article-title><source>Lancet Neurol.</source><year>2009</year><volume>8</volume><issue>7</issue><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70090-0</pub-id><pub-id pub-id-type="pmid">19539239</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooriah</surname><given-names>R</given-names></name><name><surname>Ahmed</surname><given-names>F</given-names></name></person-group><article-title>OnabotulinumtoxinA for chronic migraine: a critical appraisal</article-title><source>Ther Clin Risk Manag.</source><year>2015</year><volume>11</volume><fpage>1003</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">26170679</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cernuda-Moroll&#x000f3;n</surname><given-names>E</given-names></name><name><surname>Ramon</surname><given-names>C</given-names></name><name><surname>Martinez-Camblor</surname><given-names>P</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine</article-title><source>Pain.</source><year>2015</year><volume>156</volume><issue>5</issue><fpage>820</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000119</pub-id><pub-id pub-id-type="pmid">25735000</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luvisetto</surname><given-names>S</given-names></name><name><surname>Gazerani</surname><given-names>P</given-names></name><name><surname>Cianchetti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Botulinum toxin type A as a therapeutic agent against headache and related disorders</article-title><source>Toxins.</source><year>2015</year><volume>7</volume><issue>9</issue><fpage>3818</fpage><lpage>3844</lpage><pub-id pub-id-type="doi">10.3390/toxins7093818</pub-id><pub-id pub-id-type="pmid">26404377</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Strassman</surname><given-names>AM</given-names></name><name><surname>Novack</surname><given-names>V</given-names></name><etal/></person-group><article-title>Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors&#x02019; responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle?</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>9</issue><fpage>875</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1177/0333102416636843</pub-id><pub-id pub-id-type="pmid">26984967</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzocchio</surname><given-names>R</given-names></name><name><surname>Caleo</surname><given-names>M</given-names></name></person-group><article-title>More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system</article-title><source>Neuroscientist.</source><year>2015</year><volume>21</volume><issue>1</issue><fpage>44</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1177/1073858414524633</pub-id><pub-id pub-id-type="pmid">24576870</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bomba-Warczak</surname><given-names>E</given-names></name><name><surname>Vevea</surname><given-names>JD</given-names></name><name><surname>Brittain</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Interneuronal transfer and distal action of tetanus toxin and botulinum neurotoxins A and D in central neurons</article-title><source>Cell Rep.</source><year>2016</year><volume>16</volume><issue>7</issue><fpage>1974</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.06.104</pub-id><pub-id pub-id-type="pmid">27498860</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>BB</given-names></name><name><surname>Francis</surname><given-names>J</given-names></name><name><surname>Brin</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection</article-title><source>Neuroscience.</source><year>2017</year><volume>352</volume><fpage>155</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2017.03.049</pub-id><pub-id pub-id-type="pmid">28389376</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>CS</given-names></name><name><surname>Becerra</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal</article-title><source>Front Hum Neurosci.</source><year>2016</year><volume>10</volume><fpage>497</fpage><pub-id pub-id-type="doi">10.3389/fnhum.2016.00497</pub-id><pub-id pub-id-type="pmid">27766076</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Allergan Ltd. BOTOX 50 Allergan units: UK summary of product characteristics. 2015. <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk">https://www.medicines.org.uk</ext-link>. Accessed 11 Jan 2017.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naumann</surname><given-names>M</given-names></name><name><surname>Boo</surname><given-names>LM</given-names></name><name><surname>Ackerman</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Immunogenicity of botulinum toxins</article-title><source>J Neural Transm.</source><year>2013</year><volume>120</volume><fpage>275</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s00702-012-0893-9</pub-id><pub-id pub-id-type="pmid">23008029</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Medicines and Healthcare Products Regulatory Agency. Botox (Botulinum toxin type A): PL 00426/0074-0105; PL 00426/0118-0025; PL 00426/0119-0007: UKPAR. <ext-link ext-link-type="uri" xlink:href="http://www.mhra.gov.uk">http://www.mhra.gov.uk</ext-link>. Accessed 1 Mar 2017.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Turkel</surname><given-names>CC</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial</article-title><source>Cephalalgia.</source><year>2010</year><volume>30</volume><issue>7</issue><fpage>793</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1177/0333102410364676</pub-id><pub-id pub-id-type="pmid">20647170</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Aurora</surname><given-names>SK</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial</article-title><source>Cephalalgia.</source><year>2010</year><volume>30</volume><issue>7</issue><fpage>804</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1177/0333102410364677</pub-id><pub-id pub-id-type="pmid">20647171</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Turkel</surname><given-names>CC</given-names></name><name><surname>DeGryse</surname><given-names>RE</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program</article-title><source>Headache.</source><year>2010</year><volume>50</volume><issue>6</issue><fpage>921</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2010.01678.x</pub-id><pub-id pub-id-type="pmid">20487038</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Winner</surname><given-names>P</given-names></name><name><surname>Freeman</surname><given-names>MC</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program</article-title><source>Headache.</source><year>2011</year><volume>51</volume><issue>9</issue><fpage>1358</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2011.01990.x</pub-id><pub-id pub-id-type="pmid">21883197</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Halker</surname><given-names>R</given-names></name><name><surname>Pozo-Rosich</surname><given-names>P</given-names></name><etal/></person-group><article-title>The impact of onabotulinumtoxinA on severe headache days: preempt 24-week pooled analysis [abstract no. PF28 plus poster]</article-title><source>Headache.</source><year>2016</year><volume>56</volume><issue>Suppl 1</issue><fpage>27</fpage><lpage>28</lpage></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matharu</surname><given-names>M</given-names></name><name><surname>Halker</surname><given-names>R</given-names></name><name><surname>Pozo-Rosich</surname><given-names>P</given-names></name><etal/></person-group><article-title>The impact of onabotulinumtoxinA on severe headache days: preempt 24-week pooled analysis [abstract no. EHMTC-0156 plus poster]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>34</fpage><lpage>35</lpage></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Therapeutic Goods Administration. Australian public assessment report for botulinum toxin type A. <ext-link ext-link-type="uri" xlink:href="http://www.tga.gov.au">http://www.tga.gov.au</ext-link>. Accessed 7 Mar 2017.</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Subcommittee of the International Headache Society</collab></person-group><article-title>The international classification of headache disorders: 2nd edition</article-title><source>Cephalalgia</source><year>2004</year><volume>24</volume><issue>Suppl 1</issue><fpage>9</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">14979299</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>A</given-names></name><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program</article-title><source>Headache.</source><year>2010</year><volume>50</volume><issue>9</issue><fpage>1406</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2010.01766.x</pub-id><pub-id pub-id-type="pmid">20958294</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Technology appraisal guidance [TA260]. 2012. <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk">https://www.nice.org.uk</ext-link>. Accessed 23 Mar 2017.</mixed-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Blumenfeld</surname><given-names>AM</given-names></name><name><surname>Cady</surname><given-names>RK</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline</article-title><source>J Neurol Sci.</source><year>2013</year><volume>331</volume><issue>1&#x02013;2</issue><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2013.05.003</pub-id><pub-id pub-id-type="pmid">23790235</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Varon</surname><given-names>SF</given-names></name><name><surname>Grosberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine</article-title><source>Neurology.</source><year>2011</year><volume>77</volume><issue>15</issue><fpage>1465</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318232ab65</pub-id><pub-id pub-id-type="pmid">21956721</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Rosen</surname><given-names>NL</given-names></name><name><surname>Ailani</surname><given-names>J</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>9</issue><fpage>899</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1177/0333102416652092</pub-id><pub-id pub-id-type="pmid">27288354</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program</article-title><source>Acta Neurol Scand.</source><year>2014</year><volume>129</volume><issue>1</issue><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/ane.12171</pub-id><pub-id pub-id-type="pmid">24107267</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Aurora</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT</article-title><source>J Neurol Neurosurg Psychiatry.</source><year>2015</year><volume>86</volume><issue>9</issue><fpage>996</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2013-307149</pub-id><pub-id pub-id-type="pmid">25500317</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>AM</given-names></name><name><surname>Stark</surname><given-names>RJ</given-names></name><name><surname>Freeman</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study</article-title><source>J Headache Pain.</source><year>2018</year><volume>19</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1186/s10194-018-0840-8</pub-id><pub-id pub-id-type="pmid">29404713</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>AM</given-names></name><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Laranjo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Unmet clinical needs in chronic migraine: rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine</article-title><source>BMC Neurol.</source><year>2015</year><volume>15</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1186/s12883-015-0353-x</pub-id><pub-id pub-id-type="pmid">26133547</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>S</given-names></name><name><surname>Stark</surname><given-names>R</given-names></name><name><surname>Reppine</surname><given-names>A</given-names></name></person-group><article-title>Descriptive comparison of the efficacy and safety of onabotulinumtoxinA for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: COMPEL vs. PREEMPT [abstract no. PF18 plus poster]</article-title><source>Headache.</source><year>2015</year><volume>55</volume><issue>Suppl 3</issue><fpage>142</fpage></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>A</given-names></name><name><surname>Stark</surname><given-names>R</given-names></name><name><surname>Manack Adams</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of onabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: COMPEL [abstract no. EHMTC-0159 plus poster]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>27</fpage><lpage>28</lpage></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Blumenfeld A, Stark R, Manack Adams A, et al. Efficacy and safety of onabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: COMPEL [abstract no. P2.178]. Neurology. 2017:88(16 Suppl 1).</mixed-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenfeld</surname><given-names>A</given-names></name><name><surname>Tepper</surname><given-names>SJ</given-names></name><name><surname>Robbins</surname><given-names>LD</given-names></name><etal/></person-group><article-title>The effects of onabotulinumtoxinA treatment on the chronic migraine comorbidities of sleep and fatigue [abstract no. EP1078 plus poster]</article-title><source>Eur J Neurol.</source><year>2017</year><volume>24</volume><issue>Suppl 1</issue><fpage>163</fpage></element-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Blumenfeld AM, Tepper SJ, Robbins LD, et al. Effects of onabotulinumtoxinA treatment on the chronic migraine comorbidities of depression and anxiety [poster no. PO-02-028]. In: 18th International Headache Congress, 2017.</mixed-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Young WB, Lopez JI, Rothrock JF, et al. Effects of onabotulinumtoxinA treatment on disability and quality of life in patients with chronic migraine with baseline allodynia: a COMPEL subanalysis [abstract no. PF60 plus poster]. In: American Headache Society 59th Annual Scientific Meeting, 2017.</mixed-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Lopez JI, Blumenfeld AM, Young WB, et al. Effects of onabotulinumtoxinA treatment on disability and quality of life in patients with chronic migraine with baseline headache every day: a COMPEL subanalysis [abstract no. PF54 plus poster]. In: American Headache Society 59th Annual Scientific Meeting, 2017.</mixed-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Young WB, Lopez JI, Rothrock JF, et al. Effects of onabotulinumtoxinA treatment on disability and quality of life in patients with chronic migraine with baseline headache every day or allodynia: a COMPEL subanalysis [poster]. In: 3rd Congress of the European Academy of Neurology, 2017.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negro</surname><given-names>A</given-names></name><name><surname>Curto</surname><given-names>M</given-names></name><name><surname>Lionetto</surname><given-names>L</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study</article-title><source>SpringerPlus.</source><year>2015</year><volume>4</volume><fpage>826</fpage><pub-id pub-id-type="doi">10.1186/s40064-015-1636-9</pub-id><pub-id pub-id-type="pmid">26753113</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negro</surname><given-names>A</given-names></name><name><surname>Curto</surname><given-names>M</given-names></name><name><surname>Lionetto</surname><given-names>L</given-names></name><etal/></person-group><article-title>A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience</article-title><source>J Headache Pain.</source><year>2015</year><volume>17</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/s10194-016-0591-3</pub-id><pub-id pub-id-type="pmid">26792662</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Zafar</surname><given-names>HW</given-names></name><name><surname>Quarshie</surname><given-names>V</given-names></name><etal/></person-group><article-title>Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK</article-title><source>J Headache Pain.</source><year>2014</year><volume>15</volume><fpage>54</fpage><pub-id pub-id-type="doi">10.1186/1129-2377-15-54</pub-id><pub-id pub-id-type="pmid">25178393</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buture</surname><given-names>A</given-names></name><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Nimeri</surname><given-names>R</given-names></name><etal/></person-group><article-title>Analysis of patterns of response to onabotulinumtoxinA in chronic migraine in predicting long term outcome [abstract no. EHMTC-0343]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>17</fpage></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buture</surname><given-names>A</given-names></name><name><surname>Nimeri</surname><given-names>R</given-names></name><name><surname>Khalil</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long term outcome for onabotulinumtoxinA in chronic migraine; two year follow up of 302 patients from the Hull Migraine Clinic [abstract no. EHMTC-0328]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>16</fpage><lpage>17</lpage></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>F</given-names></name><name><surname>Zafar</surname><given-names>HW</given-names></name><name><surname>Buture</surname><given-names>A</given-names></name><etal/></person-group><article-title>Does analgesic overuse matter? Response to onabotulinumtoxinA in patients with chronic migraine with or without medication overuse</article-title><source>SpringerPlus.</source><year>2015</year><volume>4</volume><fpage>589</fpage><pub-id pub-id-type="doi">10.1186/s40064-015-1386-8</pub-id><pub-id pub-id-type="pmid">26543724</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>F</given-names></name><name><surname>Buture</surname><given-names>A</given-names></name><name><surname>Nimeri</surname><given-names>R</given-names></name><etal/></person-group><article-title>Does medication overuse matter? Response to onabotulinumtoxina in chronic migraine (CM) with or without medication overuse; update from real-life data [abstract no. EHMTC-0340]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>12</fpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>F</given-names></name><name><surname>Pascual</surname><given-names>J</given-names></name><name><surname>Geevarghese</surname><given-names>H</given-names></name><etal/></person-group><article-title>A 24-month, prospective, non-interventional study to describe the long term, real-life use of Botox&#x000ae; for the symptomatic treatment of adults with chronic migraine observed in practice (repose study): 6&#x000a0;months interim analysis [abstract no. LBP16 plus poster]</article-title><source>Headache.</source><year>2015</year><volume>55</volume><issue>Suppl 5</issue><fpage>264</fpage></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>J</given-names></name><name><surname>Gaul</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><etal/></person-group><article-title>Real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine: 12-month repose study interim analysis [abstract no. EHMTC-0214 plus poster]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>39</fpage><lpage>40</lpage></element-citation></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="other">Ahmed F, Gaul C, Martelletti P, et al. Real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine: the REPOSE study [poster no. PO-01-066]. In: 18th International Headache Congress, 2017.</mixed-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dom&#x000ed;nquez</surname><given-names>C</given-names></name><name><surname>Pozo-Rosich</surname><given-names>P</given-names></name><name><surname>Torres-Ferr&#x000fa;s</surname><given-names>M</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study</article-title><source>Eur J Neurol.</source><year>2017</year></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matharu</surname><given-names>M</given-names></name><name><surname>Pascual</surname><given-names>J</given-names></name><name><surname>Nilsson Remahl</surname><given-names>I</given-names></name><etal/></person-group><article-title>Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe</article-title><source>Cephalalgia.</source><year>2017</year><volume>37</volume><issue>14</issue><fpage>1384</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1177/0333102417724150</pub-id><pub-id pub-id-type="pmid">28758415</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">US National Institutes of Health. ClinicalTrials.gov identifier NCT01432379. 2016. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>. Accessed 17 Mar 2017.</mixed-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Granella</surname><given-names>F</given-names></name><name><surname>Prudenzano</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Italian guidelines for primary headaches: 2012 revised version</article-title><source>J Headache Pain.</source><year>2012</year><volume>13</volume><issue>Suppl 2</issue><fpage>31</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/s10194-012-0437-6</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Scottish Medicines Consortium. Botulinum toxin A (Botox). 2017. <ext-link ext-link-type="uri" xlink:href="https://www.scottishmedicines.org.uk">https://www.scottishmedicines.org.uk</ext-link>. Accessed 23 Mar 2017.</mixed-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matharu</surname><given-names>M</given-names></name><name><surname>Pascual</surname><given-names>J</given-names></name><name><surname>Nilsson Remahl</surname><given-names>I</given-names></name><etal/></person-group><article-title>Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union [abstract no. PO051 plus poster]</article-title><source>Cephalalgia.</source><year>2015</year><volume>35</volume><issue>Suppl 6</issue><fpage>39</fpage></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matharu</surname><given-names>M</given-names></name><name><surname>Pascual</surname><given-names>J</given-names></name><name><surname>Nilsson Remahl</surname><given-names>I</given-names></name><etal/></person-group><article-title>Real-world treatment utilization and safety of onabotulinumtoxinA for chronic migraine from an observational study in the European Union [abstract EHMTC-0143 plus poster]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>27</fpage></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Romoli</surname><given-names>M</given-names></name><name><surname>Corbelli</surname><given-names>I</given-names></name><etal/></person-group><article-title>Stopping onabotulinum treatment after the first two cycles might not be justified: results of a real-life monocentric prospective study in chronic migraine</article-title><source>Front Neurol.</source><year>2017</year><volume>8</volume><fpage>655</fpage><pub-id pub-id-type="doi">10.3389/fneur.2017.00655</pub-id><pub-id pub-id-type="pmid">29255444</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassorelli</surname><given-names>C</given-names></name><name><surname>Tedeschi</surname><given-names>G</given-names></name><name><surname>Sarchielli</surname><given-names>P</given-names></name><etal/></person-group><article-title>Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life</article-title><source>Expert Rev Neurother.</source><year>2018</year><volume>18</volume><issue>2</issue><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1080/14737175.2018.1419867</pub-id><pub-id pub-id-type="pmid">29280408</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cernuda-Moroll&#x000f3;n</surname><given-names>E</given-names></name><name><surname>Martinez-Camblor</surname><given-names>P</given-names></name><name><surname>Ramon</surname><given-names>C</given-names></name><etal/></person-group><article-title>CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine</article-title><source>Headache.</source><year>2014</year><volume>54</volume><issue>6</issue><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1111/head.12372</pub-id><pub-id pub-id-type="pmid">24673487</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>Cernuda-Moroll&#x000f3;n</surname><given-names>E</given-names></name><etal/></person-group><article-title>Calca gene polymorphism influences therapeutic response to onabotulinumtoxin A in female chronic migraine patients [abstract no. EHMTC-0368]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>80</fpage></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Ruiz</surname><given-names>M</given-names></name><name><surname>Cernuda-Moroll&#x000f3;n</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pharmacogenetics in chronic migraine: role of CALCA and TRPV1 genes in therapeutic response to onabotulinumtoxin A [abstract no. O1110]</article-title><source>Eur J Neurol.</source><year>2017</year><volume>24</volume><issue>Suppl 1</issue><fpage>25</fpage></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Buture</surname><given-names>A</given-names></name><name><surname>Nimeri</surname><given-names>R</given-names></name><etal/></person-group><article-title>OnabotulinumtoxinA in chronic migraine; predicting response to treatment based on headache days at baseline [abstract no. EHMTC-0332]</article-title><source>Cephalalgia.</source><year>2016</year><volume>36</volume><issue>Suppl 1</issue><fpage>118</fpage><lpage>119</lpage></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggeri</surname><given-names>M</given-names></name></person-group><article-title>The cost effectiveness of Botox in Italian patients with chronic migraine</article-title><source>Neurol Sci.</source><year>2014</year><volume>35</volume><issue>Suppl 1</issue><fpage>45</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s10072-014-1741-5</pub-id><pub-id pub-id-type="pmid">24867835</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batty</surname><given-names>AJ</given-names></name><name><surname>Hansen</surname><given-names>RN</given-names></name><name><surname>Bloudek</surname><given-names>LM</given-names></name><etal/></person-group><article-title>The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK</article-title><source>J Med Econ.</source><year>2013</year><volume>16</volume><issue>7</issue><fpage>877</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.3111/13696998.2013.802694</pub-id><pub-id pub-id-type="pmid">23647483</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><mixed-citation publication-type="other">Kollewe K, Oberling M, Kiszka M, et al. OnabotulinumtoxinA for the symptomatic treatment of chronic migraine: REPOSE study 12-month interim analysis of health-economic indicators in German patients [abstract no. LB 899]. In: 89th Congress of the German Society of Neurology, 2016.</mixed-citation></ref></ref-list></back></article>